Report cover image

Global Insulin Glargine and Lispro Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published May 17, 2025
Length 195 Pages
SKU # APRC20361920

Description

Summary

According to APO Research, The global Insulin Glargine and Lispro market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Insulin Glargine and Lispro is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Insulin Glargine and Lispro is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Insulin Glargine and Lispro is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Insulin Glargine and Lispro is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Insulin Glargine and Lispro include Sanofi S.A, Merck & Co., Eli Lilly and Company, Wockhardt Ltd., SAJA Pharmaceuticals, Novo Nordisk A/S, Julphar Diabetes LLC, Gan & Lee Pharmaceutical Ltd. and Cipla Limited, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Insulin Glargine and Lispro, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Insulin Glargine and Lispro, also provides the sales of main regions and countries. Of the upcoming market potential for Insulin Glargine and Lispro, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Insulin Glargine and Lispro sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Insulin Glargine and Lispro market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Insulin Glargine and Lispro sales, projected growth trends, production technology, application and end-user industry.

Insulin Glargine and Lispro Segment by Company

Sanofi S.A
Merck & Co.
Eli Lilly and Company
Wockhardt Ltd.
SAJA Pharmaceuticals
Novo Nordisk A/S
Julphar Diabetes LLC
Gan & Lee Pharmaceutical Ltd.
Cipla Limited
Biocon Limited
Insulin Glargine and Lispro Segment by Type

Branded Drug
Biosimilar Drug
Insulin Glargine and Lispro Segment by Application

Type I Dibetes
Type II Dibetes
Insulin Glargine and Lispro Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insulin Glargine and Lispro market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Insulin Glargine and Lispro and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insulin Glargine and Lispro.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Insulin Glargine and Lispro in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Insulin Glargine and Lispro manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Insulin Glargine and Lispro sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Insulin Glargine and Lispro Market by Type
1.2.1 Global Insulin Glargine and Lispro Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Branded Drug
1.2.3 Biosimilar Drug
1.3 Insulin Glargine and Lispro Market by Application
1.3.1 Global Insulin Glargine and Lispro Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Type I Dibetes
1.3.3 Type II Dibetes
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Insulin Glargine and Lispro Market Dynamics
2.1 Insulin Glargine and Lispro Industry Trends
2.2 Insulin Glargine and Lispro Industry Drivers
2.3 Insulin Glargine and Lispro Industry Opportunities and Challenges
2.4 Insulin Glargine and Lispro Industry Restraints
3 Global Market Growth Prospects
3.1 Global Insulin Glargine and Lispro Revenue Estimates and Forecasts (2020-2031)
3.2 Global Insulin Glargine and Lispro Revenue by Region
3.2.1 Global Insulin Glargine and Lispro Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Insulin Glargine and Lispro Revenue by Region (2020-2025)
3.2.3 Global Insulin Glargine and Lispro Revenue by Region (2026-2031)
3.2.4 Global Insulin Glargine and Lispro Revenue Market Share by Region (2020-2031)
3.3 Global Insulin Glargine and Lispro Sales Estimates and Forecasts 2020-2031
3.4 Global Insulin Glargine and Lispro Sales by Region
3.4.1 Global Insulin Glargine and Lispro Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Insulin Glargine and Lispro Sales by Region (2020-2025)
3.4.3 Global Insulin Glargine and Lispro Sales by Region (2026-2031)
3.4.4 Global Insulin Glargine and Lispro Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Insulin Glargine and Lispro Revenue by Manufacturers
4.1.1 Global Insulin Glargine and Lispro Revenue by Manufacturers (2020-2025)
4.1.2 Global Insulin Glargine and Lispro Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Insulin Glargine and Lispro Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Insulin Glargine and Lispro Sales by Manufacturers
4.2.1 Global Insulin Glargine and Lispro Sales by Manufacturers (2020-2025)
4.2.2 Global Insulin Glargine and Lispro Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Insulin Glargine and Lispro Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Insulin Glargine and Lispro Sales Price by Manufacturers (2020-2025)
4.4 Global Insulin Glargine and Lispro Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Insulin Glargine and Lispro Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Insulin Glargine and Lispro Manufacturers, Product Type & Application
4.7 Global Insulin Glargine and Lispro Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Insulin Glargine and Lispro Market CR5 and HHI
4.8.2 2024 Insulin Glargine and Lispro Tier 1, Tier 2, and Tier 3
5 Insulin Glargine and Lispro Market by Type
5.1 Global Insulin Glargine and Lispro Revenue by Type
5.1.1 Global Insulin Glargine and Lispro Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Insulin Glargine and Lispro Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Insulin Glargine and Lispro Revenue Market Share by Type (2020-2031)
5.2 Global Insulin Glargine and Lispro Sales by Type
5.2.1 Global Insulin Glargine and Lispro Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Insulin Glargine and Lispro Sales by Type (2020-2031) & (L)
5.2.3 Global Insulin Glargine and Lispro Sales Market Share by Type (2020-2031)
5.3 Global Insulin Glargine and Lispro Price by Type
6 Insulin Glargine and Lispro Market by Application
6.1 Global Insulin Glargine and Lispro Revenue by Application
6.1.1 Global Insulin Glargine and Lispro Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Insulin Glargine and Lispro Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Insulin Glargine and Lispro Revenue Market Share by Application (2020-2031)
6.2 Global Insulin Glargine and Lispro Sales by Application
6.2.1 Global Insulin Glargine and Lispro Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Insulin Glargine and Lispro Sales by Application (2020-2031) & (L)
6.2.3 Global Insulin Glargine and Lispro Sales Market Share by Application (2020-2031)
6.3 Global Insulin Glargine and Lispro Price by Application
7 Company Profiles
7.1 Sanofi S.A
7.1.1 Sanofi S.A Comapny Information
7.1.2 Sanofi S.A Business Overview
7.1.3 Sanofi S.A Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Sanofi S.A Insulin Glargine and Lispro Product Portfolio
7.1.5 Sanofi S.A Recent Developments
7.2 Merck & Co.
7.2.1 Merck & Co. Comapny Information
7.2.2 Merck & Co. Business Overview
7.2.3 Merck & Co. Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Merck & Co. Insulin Glargine and Lispro Product Portfolio
7.2.5 Merck & Co. Recent Developments
7.3 Eli Lilly and Company
7.3.1 Eli Lilly and Company Comapny Information
7.3.2 Eli Lilly and Company Business Overview
7.3.3 Eli Lilly and Company Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Eli Lilly and Company Insulin Glargine and Lispro Product Portfolio
7.3.5 Eli Lilly and Company Recent Developments
7.4 Wockhardt Ltd.
7.4.1 Wockhardt Ltd. Comapny Information
7.4.2 Wockhardt Ltd. Business Overview
7.4.3 Wockhardt Ltd. Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Wockhardt Ltd. Insulin Glargine and Lispro Product Portfolio
7.4.5 Wockhardt Ltd. Recent Developments
7.5 SAJA Pharmaceuticals
7.5.1 SAJA Pharmaceuticals Comapny Information
7.5.2 SAJA Pharmaceuticals Business Overview
7.5.3 SAJA Pharmaceuticals Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 SAJA Pharmaceuticals Insulin Glargine and Lispro Product Portfolio
7.5.5 SAJA Pharmaceuticals Recent Developments
7.6 Novo Nordisk A/S
7.6.1 Novo Nordisk A/S Comapny Information
7.6.2 Novo Nordisk A/S Business Overview
7.6.3 Novo Nordisk A/S Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Novo Nordisk A/S Insulin Glargine and Lispro Product Portfolio
7.6.5 Novo Nordisk A/S Recent Developments
7.7 Julphar Diabetes LLC
7.7.1 Julphar Diabetes LLC Comapny Information
7.7.2 Julphar Diabetes LLC Business Overview
7.7.3 Julphar Diabetes LLC Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Julphar Diabetes LLC Insulin Glargine and Lispro Product Portfolio
7.7.5 Julphar Diabetes LLC Recent Developments
7.8 Gan & Lee Pharmaceutical Ltd.
7.8.1 Gan & Lee Pharmaceutical Ltd. Comapny Information
7.8.2 Gan & Lee Pharmaceutical Ltd. Business Overview
7.8.3 Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Product Portfolio
7.8.5 Gan & Lee Pharmaceutical Ltd. Recent Developments
7.9 Cipla Limited
7.9.1 Cipla Limited Comapny Information
7.9.2 Cipla Limited Business Overview
7.9.3 Cipla Limited Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Cipla Limited Insulin Glargine and Lispro Product Portfolio
7.9.5 Cipla Limited Recent Developments
7.10 Biocon Limited
7.10.1 Biocon Limited Comapny Information
7.10.2 Biocon Limited Business Overview
7.10.3 Biocon Limited Insulin Glargine and Lispro Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Biocon Limited Insulin Glargine and Lispro Product Portfolio
7.10.5 Biocon Limited Recent Developments
8 North America
8.1 North America Insulin Glargine and Lispro Market Size by Type
8.1.1 North America Insulin Glargine and Lispro Revenue by Type (2020-2031)
8.1.2 North America Insulin Glargine and Lispro Sales by Type (2020-2031)
8.1.3 North America Insulin Glargine and Lispro Price by Type (2020-2031)
8.2 North America Insulin Glargine and Lispro Market Size by Application
8.2.1 North America Insulin Glargine and Lispro Revenue by Application (2020-2031)
8.2.2 North America Insulin Glargine and Lispro Sales by Application (2020-2031)
8.2.3 North America Insulin Glargine and Lispro Price by Application (2020-2031)
8.3 North America Insulin Glargine and Lispro Market Size by Country
8.3.1 North America Insulin Glargine and Lispro Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Insulin Glargine and Lispro Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Insulin Glargine and Lispro Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
9 Europe
9.1 Europe Insulin Glargine and Lispro Market Size by Type
9.1.1 Europe Insulin Glargine and Lispro Revenue by Type (2020-2031)
9.1.2 Europe Insulin Glargine and Lispro Sales by Type (2020-2031)
9.1.3 Europe Insulin Glargine and Lispro Price by Type (2020-2031)
9.2 Europe Insulin Glargine and Lispro Market Size by Application
9.2.1 Europe Insulin Glargine and Lispro Revenue by Application (2020-2031)
9.2.2 Europe Insulin Glargine and Lispro Sales by Application (2020-2031)
9.2.3 Europe Insulin Glargine and Lispro Price by Application (2020-2031)
9.3 Europe Insulin Glargine and Lispro Market Size by Country
9.3.1 Europe Insulin Glargine and Lispro Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Insulin Glargine and Lispro Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Insulin Glargine and Lispro Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Netherlands
10 China
10.1 China Insulin Glargine and Lispro Market Size by Type
10.1.1 China Insulin Glargine and Lispro Revenue by Type (2020-2031)
10.1.2 China Insulin Glargine and Lispro Sales by Type (2020-2031)
10.1.3 China Insulin Glargine and Lispro Price by Type (2020-2031)
10.2 China Insulin Glargine and Lispro Market Size by Application
10.2.1 China Insulin Glargine and Lispro Revenue by Application (2020-2031)
10.2.2 China Insulin Glargine and Lispro Sales by Application (2020-2031)
10.2.3 China Insulin Glargine and Lispro Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Insulin Glargine and Lispro Market Size by Type
11.1.1 Asia Insulin Glargine and Lispro Revenue by Type (2020-2031)
11.1.2 Asia Insulin Glargine and Lispro Sales by Type (2020-2031)
11.1.3 Asia Insulin Glargine and Lispro Price by Type (2020-2031)
11.2 Asia Insulin Glargine and Lispro Market Size by Application
11.2.1 Asia Insulin Glargine and Lispro Revenue by Application (2020-2031)
11.2.2 Asia Insulin Glargine and Lispro Sales by Application (2020-2031)
11.2.3 Asia Insulin Glargine and Lispro Price by Application (2020-2031)
11.3 Asia Insulin Glargine and Lispro Market Size by Country
11.3.1 Asia Insulin Glargine and Lispro Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Insulin Glargine and Lispro Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Insulin Glargine and Lispro Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Insulin Glargine and Lispro Market Size by Type
12.1.1 SAMEA Insulin Glargine and Lispro Revenue by Type (2020-2031)
12.1.2 SAMEA Insulin Glargine and Lispro Sales by Type (2020-2031)
12.1.3 SAMEA Insulin Glargine and Lispro Price by Type (2020-2031)
12.2 SAMEA Insulin Glargine and Lispro Market Size by Application
12.2.1 SAMEA Insulin Glargine and Lispro Revenue by Application (2020-2031)
12.2.2 SAMEA Insulin Glargine and Lispro Sales by Application (2020-2031)
12.2.3 SAMEA Insulin Glargine and Lispro Price by Application (2020-2031)
12.3 SAMEA Insulin Glargine and Lispro Market Size by Country
12.3.1 SAMEA Insulin Glargine and Lispro Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Insulin Glargine and Lispro Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Insulin Glargine and Lispro Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Insulin Glargine and Lispro Value Chain Analysis
13.1.1 Insulin Glargine and Lispro Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Insulin Glargine and Lispro Production Mode & Process
13.2 Insulin Glargine and Lispro Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Insulin Glargine and Lispro Distributors
13.2.3 Insulin Glargine and Lispro Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.